Ehsan Hadi, MD
Neurology · Carmichael, CANPI 1770684326
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $14,245 of the $20,239 with a category attached, or 70.4%. 12 manufacturers reported payments, led by Acorda Therapeutics, Inc at 47.7% of the total.
Across 48 payments — averaging $421.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Acorda Therapeutics, Inc$10K
- Amneal Pharmaceuticals LLC$3K
- MDD US Operations, LLC$2K
- Boston Scientific$1K
- Merz Pharmaceuticals, LLC$1K
- Acadia Pharmaceuticals Inc$1K
- plus $2K from 6 others
Across 9 payments — averaging $5755.56 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Acadia Pharmaceuticals Inc$52K
What the payments were for
- Consulting fees$2,77514%
- Speaking & faculty fees$14,24570%
- Travel & lodging$1,4887%
- Food & beverage$1,5398%
- Education$1921%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Acorda Therapeutics, Inc | 7 | $9,645 |
| Amneal Pharmaceuticals LLC | 2 | $3,073 |
| MDD US Operations, LLC | 2 | $2,137 |
| Boston Scientific | 11 | $1,180 |
| Merz Pharmaceuticals, LLC | 2 | $1,100 |
| Acadia Pharmaceuticals Inc | 3 | $1,014 |
| Medtronic | 8 | $972 |
| AbbVie(2 entities) | 8 | $704 |
| Teva Pharmaceuticals USA, Inc. | 2 | $192 |
| Abbott | 1 | $107 |
| AstraZeneca | 1 | $95 |
| Asahi Intecc USA, Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INBRIJA$9,645
- RYTARY$3,000
- XEOMIN$1,100
- NUPLAZID$993
- PERCEPT PC BRAINSENSE$809
- VERCISE$656
- BOTOX$400
- APOKYN$137
- Duopa$125
- GENERAL DBS$111
- AMPLATZER Occluders$107
How this compares
$20,239 in reported general payments places this provider in the 85th percentile of 1,996 neurology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RytaryCarbidopa/Levodopa | 135 | $278,816 |
| AustedoDeutetrabenazine | 24 | $169,755 |
| InbrijaLevodopa | 14 | $86,609 |
| IngrezzaValbenazine Tosylate | 11 | $82,197 |
| NourianzIstradefylline | 29 | $70,056 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 1,436 | $67,605 |
| Rasagiline Mesylate | 188 | $54,203 |
| GocovriAmantadine Hcl | 18 | $45,717 |
| OngentysOpicapone | 24 | $27,229 |
| Entacapone | 115 | $23,962 |
| AmantadineAmantadine Hcl | 284 | $16,753 |
| LinzessLinaclotide | 12 | $12,662 |
| Primidone | 355 | $12,228 |
| Propranolol Hcl | 295 | $7,804 |
| Droxidopa | 15 | $7,107 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Amneal Pharmaceuticals LLCRytary | $3,073 | $278,816135 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $192 | $169,75524 claims |
| Acorda Therapeutics, IncInbrija | $9,645 | $86,60914 claims |
| MDD US Operations, LLCGocovri | $2,137 | $45,71718 claims |
| AbbVieLinzess | $704 | $12,66212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,996 neurology providers in California.
Other neurology in Carmichael
- Andrew BlumenfeldCarlsbad$4.9M
- Khashayar DashtipourLoma Linda$3.3M
- Regina BerkovichWest Hollywood$3M
- Daniel BandariNewport Beach$2.6M
- Perry ShiehLos Angeles$2.4M
- Sandeep ThakkarIrvine$2M
- David LiebeskindLos Angeles$1.9M
- Jack SchimCarlsbad$1.7M
- Parshaw DorrizMission Viejo$1.5M
- Benjamin FrishbergCarlsbad$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.